New class of antigen-specific cancer immunotherapy
based on an off-the-shelf antigen presenting cell line

News

Nous recherchons un technicien de production – environnement GMP (H/F)

2023-02

Technicien de production – environnement GMP (H/F)

Vous effectuez toutes les étapes du processus de fabrication GMP et vous travaillez en étroite collaboration avec les départements R&D, QC et QA. Vous rapportez au Responsable de Production.

Les

Read more about Nous recherchons un technicien de production – environnement GMP (H/F)

Publication of a new article in the peer-reviewed journal "Genes and Cancer"

2023-02

We are very pleased to inform you about the publication of a new scientific paper in the peer-reviewed journal "Genes and Cancer" as a "Research Perspective". Article is entitled: Leveraging a powerful allogeneic dendritic cell line towards

Read more about Publication of a new article in the peer-reviewed journal "Genes and Cancer"

PUBLICATION OF A NEW SCIENTIFIC ARTICLE in the "International Journal of Molecular Sciences"

2023-01

We are very pleased to inform you about the publication of a new scientific article in the "International Journal of Molecular Sciences" in a special issue entitled "Dendritic Cell and Cancer Therapy 2.0"!

Article is entitled: A New Plasmacytoid

Read more about PUBLICATION OF A NEW SCIENTIFIC ARTICLE in the "International Journal of Molecular Sciences"

PDCline Pharma presents first immunological results from phase I/II trial with PDClung01 at ESMO-IO 2022

2022-12

Treatment with PDC*lung01 induces anti-tumor immune response in significant number of patients which appears to be enhanced by combination with pembrolizumab

Liège, Belgium, and Grenoble, France, December 8, 2022 – PDC*line Pharma, a clinical stage

Read more about PDC*line Pharma presents first immunological results from phase I/II trial with PDC*lung01 at ESMO-IO 2022

PDC*line Pharma will be presenting a poster at the 2022 ESMO Immuno-Oncology Annual Congress

2022-12

PDC*line Pharma will be presenting a poster at the 2022 European Society for Medical Oncology I-O (ESMO Immuno-Oncology) Annual Congress taking place from 7 to 9 December 2022, in Geneva, Switzerland. The poster will highlight immunological data from

Read more about PDC*line Pharma will be presenting a poster at the 2022 ESMO Immuno-Oncology Annual Congress

linkedin twitter

PDC*line Pharma

Founded in April 2014 in Grenoble (France) as a spin-off of the French Blood Bank (Etablissement Français du Sang, EFS), PDC*line Pharma is a Belgian-French biotech company that is developing a novel class of off-the-shelf cancer immunotherapies based on a proprietary Plasmacytoid Dendritic Cell line (PDC*line) pre-loaded with peptides that are derived from target tumor antigens. Based on a robust preclinical package and a first-in-human phase Ib feasibility study in melanoma, PDC*line Pharma is focusing on lung cancer with a new candidate in clinical development (PDC*lung) and on neoantigens (PDC*Neo). PDC*line Pharma comprises a team of highly skilled professionals based in Liège (Belgium) and Grenoble (France).

About us

A first in class Plasmacytoid Dendritic cell line, PDC*line providing unmatched advantages

Potent & effective

Induction of a strong cytotoxic immune response directed against a selection of tumour antigens

Scalable & convenient

Simple production of a large quantity of a highly qualified off-the-shelf product

Versatile & applicable to any cancers

The peptides can easily be changed to target a specific cancer type

Management Team

Eric Halioua

Laurent Levy

Dr. Joel Plumas

Claude DEDRY

Dr. Channa Debruyne

Candidate products

Melanoma

Melanoma is the most lethal form of skin cancer, representing 2% of all newly diagnosed cancer cases (232,000 new cases and 55,000 deaths worldwide in 2012). It is also the leading cancer in terms of incidence increase (+ 10% per year) and one of the most common cancers in young adults (18-35 years).

Melanoma is often easier to detect in its early stages than most cancers. However, it is also more likely to spread (metastasize) to other parts of the body, and 16% of patients are first diagnosed at an advanced stage. Despite new treatments, prognosis for this late-stage disease is very unfavorable (5-year mortality rate of 85%).

Read more about PDC mel

Lung Cancer

Lung cancer is the most common malignancy worldwide for male patients and for both sexes combined (2.1 million new cases per year), and the third most common for female patients (after breast and colorectal cancers). Deaths from lung cancer exceed those from any other malignancy globally, with the number of lung-cancer-related deaths worldwide for 2018 estimated at 1.8 million (Globocan 2018), representing 18.4% for both sexes. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, representing 80% of cases.

Read more about Lung Cancer

Technology

PDC*line, our proprietary allogeneic cell line of Plasmacytoid Dendritic Cells solves the industrial limitations faced by immunotherapies based on dendritic cells currently on the market or in clinical development. Additionally PDC*line is much more potent than conventional dendritic cells to expand anti-tumor CD8+ T cells in vitro.

About our technology